Selank UK: Research Reference 2026

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed as a stable analogue of tuftsin, a natural immunomodulatory peptide. The peptide was designed to combine the immunomodulatory properties of tuftsin with anxiolytic effects, creating a compound with dual activity in neuroimmune research.

The peptide is a 7-amino-acid sequence with a molecular weight of approximately 751.9 Da. Selank was developed to be resistant to proteolytic degradation while maintaining affinity for the same cellular targets as tuftsin. The C-terminal proline residue contributes to stability and receptor interactions.

For UK research laboratories, Selank serves as a reference compound for studies examining neuroimmune interactions, anxiolytic mechanisms, and the relationship between immune modulation and central nervous system function. The peptide is not licensed as a medicine and is supplied for research use only.

Selank is a synthetic heptapeptide with the following structural characteristics:

• Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (7 amino acids)
• Molecular weight: Approximately 751.9 Da
• Origin: Synthetic analogue of tuftsin, a natural immunomodulatory peptide
• Stability: Resistant to proteolytic degradation due to sequence modifications
• C-terminus: Proline (contributes to stability and receptor binding)

The peptide is a partial sequence of tuftsin with modifications conferring enhanced stability and anxiolytic activity. The proline-rich sequence creates a rigid secondary structure that may facilitate receptor interactions. The positively charged arginine and lysine residues contribute to cellular uptake and membrane interactions.

Selank operates through several mechanisms in cellular and in vitro models:

Neuroimmune Modulation

Selank modulates the expression of neuroimmune mediators in cellular models. The peptide affects the production of cytokines (IL-1β, IL-6, TNF-α) and neurotrophic factors (BDNF, NGF) in glial cells and neuronal cultures. The immunomodulatory effects are examined in the context of neuroinflammation and stress response models.

Anxiolytic Signalling

In cellular and animal models, Selank influences anxiolytic pathways through modulation of GABAergic neurotransmission. The peptide affects GABA receptor expression and function in neuronal cultures, though the exact receptor mechanism is still under investigation. The anxiolytic effects are studied in stress-response and anxiety-related cellular models.

Neurotrophic Factor Modulation

Selank upregulates brain-derived neurotrophic factor (BDNF) expression in neuronal cultures. BDNF is a key regulator of synaptic plasticity, neuronal survival, and cognitive function. The peptide's effects on BDNF are examined in the context of neuroplasticity and cognitive enhancement research.

Enkephalinase Inhibition

Selank may inhibit enkephalin-degrading enzymes (enkephalinases), prolonging the activity of endogenous opioid peptides. This mechanism is studied in cellular models examining pain modulation, stress response, and emotional regulation pathways.

Serotonin System Interactions

In cellular studies, Selank affects serotonin (5-HT) metabolism and receptor expression. The peptide modulates tryptophan hydroxylase activity and serotonin transporter function in neuronal cultures, though the exact mechanism remains under investigation.

Selank is employed across multiple research domains in UK laboratories:

Neuroimmune Research

In vitro studies examine Selank's effects on neuroimmune mediator production in glial cells (astrocytes, microglia) and neuronal cultures. Researchers study the peptide's modulation of cytokine networks, chemokine expression, and the cross-talk between immune and nervous systems in cellular models.

Anxiety and Stress Research

Cellular models of stress response examine Selank's effects on corticotropin-releasing factor (CRF) signalling, glucocorticoid receptor expression, and stress-induced neuronal changes. The peptide's anxiolytic mechanism is studied in hypothalamic and amygdalar cell cultures.

Cognitive Enhancement Research

Neuronal cultures and brain slice models examine Selank's effects on synaptic plasticity, long-term potentiation (LTP), and neurotrophic factor expression. The BDNF-modulating activity is studied in the context of memory formation, learning, and cognitive resilience.

Neuroprotection Research

Cellular models of oxidative stress and excitotoxicity examine Selank's neuroprotective effects. The peptide is studied in the context of neuronal survival, antioxidant enzyme expression, and resistance to glutamate-induced toxicity in cortical and hippocampal cultures.

Comparative Neuroactive Peptides

Selank is compared to tuftsin, semax, and other neuroactive peptides in cellular studies. Research questions examine whether the synthetic modifications produce distinct neuroimmune or anxiolytic profiles compared to the parent peptide.

UK research laboratories employ several standard cellular models for Selank studies:

Neuronal Cultures

Primary cortical, hippocampal, and hypothalamic neuronal cultures are used to examine Selank's effects on neuronal viability, morphology, and receptor expression. Endpoints include cell survival, neurite outgrowth, and electrophysiological properties.

Glial Cell Cultures

Astrocyte and microglial cultures are used to examine Selank's effects on neuroimmune mediator production. Endpoints include cytokine release (IL-1β, IL-6, TNF-α), chemokine expression, and glial activation markers.

BDNF Expression Assays

Neuronal cultures are used to measure BDNF mRNA and protein expression in response to Selank treatment. qPCR, Western blot, and ELISA approaches quantify neurotrophic factor upregulation. The peptide is compared to known BDNF inducers.

GABAergic Signalling

Cultures of GABAergic interneurons or transfected cell lines expressing GABA receptors are used to examine Selank's effects on inhibitory neurotransmission. Electrophysiological recordings and receptor binding assays quantify changes in GABAergic function.

Stress Response Models

Neuronal cultures are subjected to corticosterone, oxidative stress, or glutamate excitotoxicity, then treated with Selank to examine neuroprotective effects. Endpoints include cell viability, oxidative stress markers, and apoptosis assays.

Selank's safety profile is based on preclinical cellular and animal studies. In vitro toxicology screens using standard cell lines have not identified significant cytotoxicity at research-relevant concentrations (up to 100 μM).

In animal studies, the peptide has been well tolerated at standard research doses. The synthetic design and small size contribute to favourable safety characteristics. The peptide does not appear to produce sedation, motor impairment, or cognitive disruption in preclinical models.

The peptide's neuroimmune modulation raises theoretical considerations about immune system effects, though no significant immunosuppressive or immunostimulatory adverse effects have been reported at standard research doses. As with all research peptides, appropriate laboratory controls and dose-ranging studies are recommended.

Standard laboratory precautions apply: Selank is a research peptide, not a medicine or dietary supplement. It is supplied for in vitro and laboratory animal research only.

Selank is supplied as a lyophilised powder in research-grade vials. Standard laboratory preparation:

• Reconstitution: Bacteriostatic water (0.9% benzyl alcohol) is recommended for laboratory preparations
• Concentration: Typical research stock concentrations range from 1–10 mg/mL depending on assay requirements
• Storage: Lyophilised powder at −20 °C; reconstituted solution at 2–8 °C, protected from light
• Stability: Reconstituted solutions are stable for 7–14 days under refrigeration; for extended studies, aliquot and freeze at −20 °C
• Solubility: The peptide is generally soluble in aqueous solutions; brief vortexing may aid dissolution
• Protease sensitivity: The synthetic design confers some protease resistance, but standard protease inhibitors may be included in incubation media

The peptide's small size may result in non-specific binding to plastic surfaces; researchers should verify recovery rates. Pre-wetting tubes with BSA-containing buffer may reduce peptide loss. The peptide is light-sensitive; protect from prolonged light exposure.

Selank is not a controlled substance under the UK Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is classified as a research peptide for laboratory use and is not licensed as a medicine by the MHRA.

For UK research laboratories, Selank is available as a research-grade reference material. Sourcing should include:

• Certificate of Analysis confirming ≥98% purity (HPLC)
• Mass spectrometry identity confirmation (molecular weight ~751.9 Da)
• Batch-specific testing documentation
• Appropriate storage and shipping conditions (cold chain)
• Research-use-only labelling

Researchers should ensure compliance with institutional ethics approvals for animal studies, and adhere to standard laboratory safety protocols for peptide handling.